News
Eli Lilly & Co. will only work with telehealth firms that agree to stop selling copycat versions of weight-loss drugs, ...
Real-world results for blockbuster weight-loss meds like Ozempic, Wegovy and Zepbound aren't as impressive as those promised ...
Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per ...
A new clinical trial has revealed that tirzepatide (Zepbound) surpasses semaglutide (Wegovy) in promoting weight loss among ...
A study, which was published in The New England Journal of Medicine, found that tirzepatide (Zepbound) is more effective for ...
Since the FDA said shortages of Wegovy and Zepbound are over, compounding pharmacies are supposed to stop making copies of ...
Eli Lilly’s LLY key top-line drivers are its GLP-1 medicines, Mounjaro for type II diabetes and Zepbound for obesity. Both ...
More American teenagers now use the weight-loss drug Wegovy, as doctors and families grow more comfortable with the treatment ...
American teens are increasingly turning to the weight-loss drug Wegovy as more families and their doctors gain confidence in ...
Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...
That’s up from a rate of 9.9 prescriptions per 100,000 in 2023, the first full year that Wegovy was available to children ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results